Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{[(2S)-1-[ (3R ) - 3-amino -4-( 2-fluorophenyl ) butanoyl ] pyrrolidin - 2-y l ] methyl } benzamide is a synthetic small molecule belonging to the class of beta amino acid derivatives. It has been studied as an experimental compound and is known to act as an inhibitor of dipeptidyl peptidase IV (DPP-IV, also known as DPP4), a serine protease involved in glucose metabolism and immune regulation. The compound has not been approved for clinical use and remains primarily a research tool or probe for studying DPP-IV function[1][5]. Its molecular formula is C22H26FN3O2, with a molecular weight of approximately 383.46 g/mol[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-({(2S)-1-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-yl}methyl)benzamide.